TRCT
KTTA icon

Tower Research Capital (TRC)’s Pasithea Therapeutics KTTA Stock Holding History

Tower Research Capital (TRC)’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55K Buy
8,838
+6,984
+377% +$4.8K ﹤0.01% 4375
2026
Q1 		$1.38K Sell
1,854
-1,093
-37% -$914 ﹤0.01% 4678
2025
Q4 		$3.8K Buy
2,947
+1,730
+142% +$1.52K ﹤0.01% 4312
2025
Q3 		$891 Sell
1,217
-44
-3% -$32 ﹤0.01% 4911
2025
Q2 		$910 Sell
1,261
-2,006
-61% -$2.19K ﹤0.01% 4914
2025
Q1 		$4.25K Buy
3,267
+1,381
+73% +$2.45K ﹤0.01% 4282
2024
Q4 		$5.94K Buy
1,886
+1,285
+214% +$4.55K ﹤0.01% 4222
2024
Q3 		$3.26K Sell
601
-1,206
-67% -$5.94K ﹤0.01% 4875
2024
Q2 		$9.14K Buy
1,807
+462
+34% +$3.02K ﹤0.01% 4284
2024
Q1 		$9.75K Buy
1,345
+725
+117% +$5.15K ﹤0.01% 3797
2023
Q4 		$4.59K Sell
620
-5
-0.8% -$37 ﹤0.01% 4939
2023
Q3 		$6K Buy
625
+1
+0.2% +$11 ﹤0.01% 4656
2023
Q2 		$6.12K Sell
624
-6
-1% -$48 ﹤0.01% 4736
2023
Q1 		$5K Sell
630
-122
-16% -$1.38K ﹤0.01% 4973
2022
Q4 		$10K Buy
752
+469
+166% +$9.37K ﹤0.01% 4022
2022
Q3 		$7K Buy
283
+170
+150% +$3.99K ﹤0.01% 4896
2022
Q2 		$2K Buy
+113
New +$2.4K ﹤0.01% 5559
2022
Q1 		– Sell
-1,469
Closed -$52K – 6347
2021
Q4 		$52K Buy
1,469
+1,377
+1,497% +$71.6K ﹤0.01% 2732
2021
Q3 		$6K Buy
+92
New +$5.58K ﹤0.01% 4760

Other funds holding KTTA

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HC
Hurley Capital New York $193M AUM 25.58% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Tower Research Capital (TRC)'s KTTA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Pasithea Therapeutics (KTTA) stake by 377% in Q2 2026, buying an estimated $4.8K and bringing the position to 8,838 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4375.

Tower Research Capital (TRC) first reported a position in KTTA in Q3 2021 and has held it in 19 quarters since. The position peaked at $52K in Q4 2021. 9 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Tower Research Capital (TRC) held 8,838 shares of Pasithea Therapeutics worth $4.55K as of Q2 2026.
  • Tower Research Capital (TRC) bought 6,984 Pasithea Therapeutics shares in Q2 2026, an estimated $4.8K.
  • Pasithea Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4375 holding.
  • Tower Research Capital (TRC) first reported a position in Pasithea Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Pasithea Therapeutics position peaked at $52K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.